Skip to main content
. 2012 May 22;107(1):7–11. doi: 10.1038/bjc.2012.210

Figure 2.

Figure 2

Disease-free survival (A) and overall survival (B) were similar between the ZOL and no-ZOL arms for the overall trial population. Abbreviations: DFS=disease-free survival; OS=overall survival; ZOL=zoledronic acid (4 mg every 3 weeks); ○=censored.